272 related articles for article (PubMed ID: 21481826)
21. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ
JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
[TBL] [Abstract][Full Text] [Related]
22. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
23. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T; Miller T; Ko S
Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
[TBL] [Abstract][Full Text] [Related]
24. Aspirin for the prevention of cardiovascular morbidity.
Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
[TBL] [Abstract][Full Text] [Related]
25. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
26. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
[TBL] [Abstract][Full Text] [Related]
27. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A;
Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet therapy and anticoagulation in patients with hypertension.
Griffin G
Am Fam Physician; 2005 Mar; 71(5):897-9. PubMed ID: 15768617
[TBL] [Abstract][Full Text] [Related]
29. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
30. Aspirin in the treatment and prevention of cardiovascular disease.
Gaziano JM; Skerrett PJ; Buring JE
Haemostasis; 2000; 30 Suppl 3():1-13. PubMed ID: 11182624
[TBL] [Abstract][Full Text] [Related]
31. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
32. Primary Prevention of CVD with Aspirin: Benefits vs Risks.
Weisman SM; Brunton S
J Fam Pract; 2021 Jul; 70(6S):S41-S46. PubMed ID: 34432623
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
34. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
35. Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Hennekens CH
Curr Atheroscler Rep; 2007 Nov; 9(5):409-16. PubMed ID: 18001625
[TBL] [Abstract][Full Text] [Related]
36. A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Shah R; Khan B; Latham SB; Khan SA; Rao SV
Am J Med; 2019 Nov; 132(11):1295-1304.e3. PubMed ID: 31153866
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.
Mahmoud AN; Gad MM; Elgendy AY; Elgendy IY; Bavry AA
Eur Heart J; 2019 Feb; 40(7):607-617. PubMed ID: 30561620
[TBL] [Abstract][Full Text] [Related]
38. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
Belch J; MacCuish A; Campbell I; Cobbe S; Taylor R; Prescott R; Lee R; Bancroft J; MacEwan S; Shepherd J; Macfarlane P; Morris A; Jung R; Kelly C; Connacher A; Peden N; Jamieson A; Matthews D; Leese G; McKnight J; O'Brien I; Semple C; Petrie J; Gordon D; Pringle S; MacWalter R; ; ;
BMJ; 2008 Oct; 337():a1840. PubMed ID: 18927173
[TBL] [Abstract][Full Text] [Related]
39. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
40. Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.
Buring JE
Cleve Clin J Med; 2006 Sep; 73(9):863-70. PubMed ID: 16970138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
